MOUNJARO 15MG KWIKPEN
Item requires a valid prescription
Manufactured By LILLY PRODUCTS
Composition TIRZEPATIDE 15MG
RS 23203.10
MRP RS 25781.20
(10% OFF)
Includes all taxes
Package SIZE
( 2.4ML )
100% Authentic
Products
Free
Shipping*
Products
Return Policy
Description:
Mounjaro 15mg KwikPen
Mounjaro 15mg KwikPen (Tirzepatide 15mg) is an innovative, once-weekly subcutaneous injection manufactured by Lilly Products (Eli Lilly), representing a breakthrough in the treatment of Type 2 Diabetes Mellitus (T2DM) and weight management. As the world's first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, Tirzepatide simultaneously activates two incretin hormone pathways, delivering superior glycaemic control and clinically significant weight reduction compared to existing injectable therapies. The 15mg dose is the highest approved maintenance dose, used after dose escalation from lower strengths. Available from Shabbir Medical Hall at the best price in India, this genuine prescription KwikPen is available online with fast, reliable delivery.
BENEFITS: Mounjaro 15mg achieves average HbA1c reductions of up to 2.58% and body weight reductions of up to 15.7 kg in clinical trials (SURPASS programme). By activating both GIP and GLP-1 receptors, it enhances insulin secretion in a glucose-dependent manner, suppresses glucagon, slows gastric emptying, and promotes satiety — producing a uniquely powerful metabolic effect. Its weekly dosing schedule, combined with the user-friendly KwikPen device, makes it highly convenient for patients requiring injectable diabetes therapy.
USAGE OVERVIEW: Mounjaro 15mg is administered as a once-weekly subcutaneous injection in the abdomen, thigh, or upper arm. The 15mg dose is reached after gradual dose escalation starting at 2.5mg weekly. Always inject on the same day each week. The KwikPen is pre-filled and ready to use — no dose preparation required. Never self-initiate without physician guidance and proper injection training.
SAFETY OVERVIEW: The most common side effects are gastrointestinal — nausea, vomiting, diarrhoea, and reduced appetite — particularly during dose escalation. Rare but serious risks include pancreatitis, gallbladder disease, and a theoretical risk of thyroid C-cell tumours (based on animal data). Inform your doctor of all medical conditions and medications before starting.
Uses / Indications:
• Type 2 Diabetes Mellitus (T2DM): Adjunct to diet and exercise to improve glycaemic control in adults
• Cardiovascular Risk Reduction: Mounjaro has demonstrated cardiovascular benefits in T2DM patients with established cardiovascular disease
• Weight Management (Obesity / Overweight): As Zepbound (same molecule), Tirzepatide 15mg is approved for chronic weight management in adults with obesity (BMI >=30) or overweight (BMI >=27) with at least one weight-related comorbidity
ADDITIONAL / EMERGING USES:
• Non-alcoholic steatohepatitis (NASH) / Metabolic Associated Steatotic Liver Disease (MASLD): under clinical investigation
• Obstructive sleep apnoea in obesity: clinical data emerging
• Polycystic ovary syndrome (PCOS) with insulin resistance: off-label, specialist use
• Heart failure with preserved ejection fraction (HFpEF) in obese patients: clinical trials ongoing
Interactions / Warnings:
THYROID C-CELL TUMOUR WARNING: In animal studies, Tirzepatide caused dose-dependent thyroid C-cell tumours. It is UNKNOWN whether this risk applies to humans. Mounjaro is CONTRAINDICATED in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Report any neck masses, hoarseness, or dysphagia immediately.
PANCREATITIS: GLP-1/GIP agonists have been associated with acute pancreatitis. Discontinue Mounjaro immediately if pancreatitis is suspected. Do not restart without physician evaluation.
HYPOGLYCAEMIA RISK: Mounjaro alone has a low risk of hypoglycaemia. Risk increases significantly with concurrent insulin or sulfonylurea use. Patients and caregivers should know hypoglycaemia symptoms and management. Carry fast-acting glucose (glucose tablets, fruit juice) at all times.
DIABETIC RETINOPATHY: Rapid improvement in blood sugar control (as seen with Mounjaro) may temporarily worsen diabetic retinopathy. Patients with pre-existing retinopathy require ophthalmological monitoring.
RENAL DISEASE: No dose adjustment required for renal impairment, but dehydration from GI side effects can precipitate acute kidney injury. Ensure adequate hydration — especially during dose escalation.
HEPATIC DISEASE: No dose adjustment required for hepatic impairment. Limited data in severe hepatic impairment; use with specialist guidance.
TYPE 1 DIABETES: Mounjaro is NOT indicated for Type 1 Diabetes or diabetic ketoacidosis.
DRIVING & MACHINERY: Hypoglycaemia (especially with insulin co-use) may impair driving ability. Patients should assess their response before driving.
ELDERLY USE (>=65 years): No age-specific dose adjustment, but elderly patients may be more susceptible to GI side effects and dehydration. Monitor renal function and hydration status closely.
Pregnancy interaction:
• Mounjaro 15mg (Tirzepatide) is NOT recommended during pregnancy.
• Animal studies have shown adverse effects on foetal development at clinically relevant doses.
• Tirzepatide should be discontinued at least 2 months before a planned pregnancy.
• Women of childbearing potential must use effective contraception during treatment.
• Inform your doctor immediately if pregnancy is suspected or confirmed during treatment.
• Uncontrolled blood sugar during pregnancy poses significant risks; your physician will switch you to insulin, which is safe in pregnancy.
BREASTFEEDING:
• It is not known whether Tirzepatide is excreted in human breast milk.
• Breastfeeding is NOT recommended during treatment with Mounjaro as a precautionary measure.
• Discuss alternative feeding options with your physician.
CONTRACEPTION WARNING:
• Never stop Mounjaro without consulting your endocrinologist or diabetologist. Stopping abruptly without medical supervision may lead to significant deterioration in blood sugar control.
Expert advice:
1. MANDATORY DOSE ESCALATION — NEVER JUMP STRAIGHT TO 15MG:
• Tirzepatide must be dose-escalated gradually (2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg, each step every 4 weeks). Starting at 15mg without escalation causes severe GI side effects. Always follow the escalation plan your endocrinologist has prescribed.
2. MANAGE GI SIDE EFFECTS PROACTIVELY:
• Nausea and vomiting are the most common reasons patients discontinue Tirzepatide. Advise eating smaller, low-fat meals, avoiding spicy or greasy food, and drinking adequate fluids. GI effects typically improve within 4–8 weeks at each dose level.
3. WATCH FOR HYPOGLYCAEMIA IF ON INSULIN:
• If you use Mounjaro alongside insulin or a sulfonylurea, your doctor may reduce your insulin/sulfonylurea dose when initiating or escalating. Always carry fast-acting glucose. Monitor blood sugar more frequently during dose escalation.
4. ORAL CONTRACEPTIVE TIMING:
• If you take oral contraceptive pills, discuss with your doctor. Tirzepatide slows gastric emptying, which may reduce OCP absorption. Consider additional contraception (e.g., condom) during the first 4 weeks of each dose increase.
5. COLD CHAIN COMPLIANCE:
• Always store Mounjaro KwikPen in the refrigerator (2–8°C). Never freeze. If storing out of the fridge, use within 21 days and keep below 30°C. Use an insulated medical pouch during travel. Inspect for cloudiness before each injection — do not use if compromised.
MONITORING ADVICE:
• Blood glucose (fasting & post-prandial): Regularly, especially during dose escalation
• HbA1c: Every 3 months initially; target <7% (individualised by your endocrinologist)
• Body weight: Monthly; track progress; adjust co-medications as weight reduces
• Lipid profile (cholesterol): At baseline and periodically — weight loss often improves lipids
• Kidney function (eGFR / serum creatinine): Baseline and annually; monitor more if GI symptoms cause dehydration
• Liver function: Baseline and periodically in patients with known NAFLD/NASH
• Thyroid: Report any neck lumps, hoarseness, or swallowing difficulty immediately
• Diabetic retinopathy: Ophthalmological review within 3–6 months of starting, especially if pre-existing retinopathy
• Amylase/lipase: If any symptoms of pancreatitis develop
COMPLIANCE TIPS:
• Set a weekly phone alarm for injection day — consistency on the same day is important
• Keep a logbook or use a diabetes app to record injection dates, blood glucose readings, and weight
• If you feel nauseated on injection day, inject at bedtime — GI symptoms may be less noticeable
• Never share your KwikPen, even with family members — infection and dose confusion risk
• Rotate injection sites each week (abdomen, thighs, upper arms — document site in logbook)
SAFETY TIPS:
• Always carry a medical ID card or phone alert noting you are on Tirzepatide (risk of GI-related dehydration in emergencies)
• Carry glucose tablets if co-prescribed with insulin — hypoglycaemia can occur rapidly
• Dispose of used KwikPens in a puncture-resistant sharps container; return via pharmacy take-back scheme
• Do not take OTC NSAIDs (ibuprofen, naproxen) freely — they can worsen kidney function if you are already dehydrated from GI side effects
Side Effects:
• Nausea (most common, particularly at higher doses)
• Vomiting
• Diarrhoea
• Constipation
• Reduced appetite / decreased food intake
• Abdominal pain or discomfort
• Dyspepsia (indigestion)
COMMON SIDE EFFECTS (1 in 10 to 1 in 100 people):
• Injection site reactions: erythema, bruising, swelling, pruritus
• Fatigue and dizziness (especially early in treatment)
• Hypoglycaemia (low blood sugar) — particularly if used with insulin or sulfonylureas
• Hair loss (alopecia) — often related to rapid weight loss
• Belching and flatulence
• Elevated heart rate (mild)
SERIOUS SIDE EFFECTS — CONTACT DOCTOR IMMEDIATELY:
• Acute Pancreatitis: sudden severe upper abdominal pain radiating to the back, nausea, vomiting — discontinue Mounjaro and seek urgent care
• Gallbladder Disease (cholecystitis, cholelithiasis): right upper abdominal pain, fever, jaundice
• Severe hypoglycaemia: shakiness, confusion, cold sweats, unconsciousness (higher risk if on insulin)
• Severe gastrointestinal events: ileus, gastroparesis (rare)
• Acute kidney injury: secondary to severe dehydration from prolonged GI side effects
EMERGENCY WARNING SIGNS — SEEK IMMEDIATE MEDICAL HELP:
• Sudden severe abdominal pain with vomiting (possible pancreatitis)
• Signs of severe allergic reaction: facial swelling, difficulty breathing, rapid heartbeat (anaphylaxis)
• Neck mass, hoarseness, or difficulty swallowing (possible thyroid tumour — rare)
• Severe dehydration: dizziness, dark urine, inability to keep fluids down
How to use:
DOSE ESCALATION SCHEDULE:
• Week 1–4: 2.5mg once weekly (starting dose — not therapeutic; for tolerability)
• Week 5–8: 5mg once weekly
• Week 9–12: 7.5mg once weekly
• Week 13–16: 10mg once weekly
• Week 17–20: 12.5mg once weekly
• Week 21+: 15mg once weekly (maximum maintenance dose)
ROUTE OF ADMINISTRATION / HOW TO USE THE KWIKPEN:
• Remove KwikPen from refrigerator 30 minutes before use and allow to reach room temperature
• Inspect solution — it should be clear, colourless to slightly yellow; do not use if cloudy or containing particles
• Select injection site: abdomen (at least 5cm from navel), outer thigh, or upper arm
• Clean the skin with an alcohol swab and allow to dry
• Press the KwikPen firmly against skin; press and hold the button until the injection is complete (click sound, then hold for 5 more seconds)
• Rotate injection sites weekly to prevent skin reactions
TIMING:
• Inject once every 7 days, on the same day each week
• Can be taken at any time of day, with or without food
MISSED DOSE:
• If a dose is missed and the next dose is >4 days away: inject as soon as remembered
• If next dose is <4 days away: skip the missed dose and resume usual schedule — never double dose
STORAGE:
• Refrigerate at 2°C–8°C (36°F–46°F). Do NOT freeze.
• Can be stored at room temperature (up to 30°C) for up to 21 days
• Keep in original carton, protected from light
• Single-patient use only — never share KwikPen. Discard after use.
• Keep out of reach of children
How it works:
Mounjaro 15mg KwikPen contains Tirzepatide — the world's first dual GIP/GLP-1 receptor agonist — a novel molecule engineered by Eli Lilly using a fatty acid linker that enables once-weekly dosing.
1. GLP-1 Receptor Agonism:
• Stimulates glucose-dependent insulin secretion from pancreatic beta cells
• Suppresses glucagon release from alpha cells (reducing hepatic glucose output)
• Slows gastric emptying — blunting post-meal blood glucose spikes
• Promotes central satiety via hypothalamic GLP-1 receptors — reducing appetite and caloric intake
2. GIP Receptor Agonism (unique vs GLP-1 mono-agonists like semaglutide):
• Enhances insulin secretion synergistically with GLP-1 signalling
• Promotes adipocyte lipid metabolism — enhancing fat utilisation
• Improves insulin sensitivity in peripheral tissues (muscle, adipose tissue)
• May reduce GLP-1-associated nausea burden through GIP-mediated pathways
CLINICAL OUTCOME:
• Average HbA1c reduction: up to 2.58% (SURPASS-2 vs semaglutide 1mg)
• Average body weight reduction: up to 15.7 kg at 15mg dose (SURPASS-4)
• Superior to semaglutide 1mg in both HbA1c and weight endpoints in head-to-head trials
• Cardiovascular outcome data: positive, with reduction in MACE risk in high-CV-risk T2DM patients
Faq for medicine:
Mounjaro 15mg KwikPen (Tirzepatide 15mg) is a once-weekly injectable medication for Type 2 Diabetes in adults. As the world's first dual GIP/GLP-1 receptor agonist, it controls blood sugar, reduces HbA1c by up to 2.58%, and supports significant weight loss of up to 15.7 kg.
2. How does Mounjaro 15mg Tirzepatide KwikPen work?
Tirzepatide activates both GIP and GLP-1 receptors simultaneously — boosting insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. This dual incretin mechanism delivers superior HbA1c and weight reduction compared to GLP-1 mono-agonists like semaglutide (Ozempic/Rybelsus).
3. What is the dose of Mounjaro 15mg KwikPen Injection?
Mounjaro 15mg is the maximum maintenance dose. Patients must escalate gradually: 2.5mg for 4 weeks, then increasing by 2.5mg every 4 weeks (5mg → 7.5mg → 10mg → 12.5mg → 15mg). It is injected once weekly in abdomen, thigh, or upper arm. Always follow your endocrinologist's escalation schedule.
4. What are the side effects of Mounjaro 15mg KwikPen?
Common: nausea, vomiting, diarrhoea, reduced appetite, constipation — mainly during dose escalation, improving over time. Serious but rare: acute pancreatitis (severe abdominal pain), gallbladder disease, hypoglycaemia (with insulin). Seek urgent care for sudden severe abdominal pain or signs of allergic reaction.
5. Can I buy Mounjaro 15mg KwikPen online at the best price in India?
Yes. Buy Mounjaro 15mg KwikPen online from Shabbir Medical Hall at 10% OFF MRP (Rs 23,203.10 vs Rs 25,781.20). Valid endocrinologist/diabetologist prescription required. Fast delivery across Hyderabad, Bangalore, Mumbai, Delhi, and Chennai with cold-chain compliant packaging.
Medicine interaction:
INSULIN & INSULIN SECRETAGOGUES (HIGH RISK — dose adjustment required):
• Insulin (all types: rapid, basal, mixed): concurrent use significantly increases hypoglycaemia risk
• Sulfonylureas (glibenclamide, glipizide, glimepiride): enhanced hypoglycaemia risk — consider dose reduction of sulfonylurea when initiating Mounjaro
ORAL MEDICATIONS WITH NARROW THERAPEUTIC INDEX:
• Tirzepatide slows gastric emptying — may alter absorption timing and peak levels of oral drugs
• Warfarin / oral anticoagulants: monitor INR closely; onset of absorption may be delayed
• Oral contraceptives: reduced absorption possible — consider using non-oral contraception or additional barrier methods during first 4 weeks of each dose escalation step
• Levothyroxine, digoxin: monitor levels; absorption kinetics may be affected
ANTIHYPERTENSIVES:
• Significant weight loss with Tirzepatide may reduce blood pressure — antihypertensive doses may need to be adjusted to avoid hypotension
LIPID-LOWERING MEDICINES:
• Weight loss may improve lipid profiles; statin or fibrate doses may require review over time
VACCINE INTERACTIONS:
• Alcohol increases hypoglycaemia risk, particularly with insulin co-administration
• Alcohol may worsen GI side effects — limit consumption during treatment
SUPPLEMENT INTERACTIONS:
• No major documented interactions, but always inform your pharmacist of all supplements and herbal products; some may affect blood sugar or GI function
